NDAINTRAVENOUSFOR SUSPENSION
Approved
Oct 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
5/8 — Partial
LUMASON (sulfur hexafluoride) by Bracco is ultrasound contrast activity [moa]. Approved for contrast agent for ultrasound imaging [epc]. First approved in 2014.
Drug data last refreshed 20h ago
Mechanism of Action
Ultrasound Contrast Activity
Pharmacologic Class:
Contrast Agent for Ultrasound Imaging
Indications (1)
Clinical Trials (4)
Lumason® Infusion vs. Bolus Administrations
Started Jul 2024
106 enrolled
Heart Diseases
Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142
Started Oct 2015
174 enrolled
Coronary Artery Disease
Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography
Started Oct 2015
13 enrolled
Heart Disease
Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141
Started Sep 2015
175 enrolled
Coronary Artery Disease
Worked on LUMASON at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.